Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

被引：0
|
作者：
Mei Dong
Zhi-Qiang Ning
Pu-Yuan Xing
Jia-Lian Xu
Hai-Xiang Cao
Gui-Fang Dou
Zhi-Yun Meng
Yuan-Kai Shi
Xian-Ping Lu
Feng-Yi Feng
机构：
[1] Chinese Academy of Medical Sciences,Department of Medical Oncology, Cancer Institute and Hospital
[2] Chipscreen Biosciences Ltd.,Laboratory of Drug Metabolism and Pharmacokinetics
[3] Tigermed Consulting Ltd.,undefined
[4] Institute of Transfusion Medicine,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Chidamide; HDAC inhibitor; Phase I; Solid tumor; Lymphoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1413 / 1422
页数：9
相关论文
共 50 条
  • [31] Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors
    Huie, M
    Carducci, M
    Liu, G
    Wilding, GG
    Marnocha, R
    Izquierda, M
    Thomas, J
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (06): : 613 - 617
  • [32] A phase I study of bortezomib and temozolomide in patients with advanced solid tumors
    Portnow, J.
    Frankel, P.
    Koehler, S.
    Twardowski, P.
    Shibata, S.
    Martel, C.
    Morgan, R.
    Cristea, M.
    Chow, W.
    Lim, D.
    Chung, V.
    Reckamp, K.
    Leong, L.
    Synold, T. W.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (02) : 505 - 514
  • [33] A phase i study of ixazomib and erlotinib in patients with advanced solid tumors
    Shumei Kato
    Jacob J. Adashek
    Vivek Subbiah
    Siqing Fu
    Mianen Sun
    Ly Nguyen
    Elsa J. Brown
    Timothy A. Yap
    Daniel D. Karp
    Sarina A. Piha-Paul
    David S. Hong
    Investigational New Drugs, 2022, 40 : 99 - 105
  • [34] A Phase I Study of Histone Deacetylase Inhibitor, Pracinostat (SB939), in Pediatric Patients With Refractory Solid Tumors: IND203 a Trial of the NCIC IND Program/C17 Pediatric Phase I Consortium
    Zorzi, Alexandra P.
    Bernstein, Mark
    Samson, Yvan
    Wall, Donna A.
    Desai, Sunil
    Nicksy, Darcy
    Wainman, Nancy
    Eisenhauer, Elizabeth
    Baruchel, Sylvain
    PEDIATRIC BLOOD & CANCER, 2013, 60 (11) : 1868 - 1874
  • [35] Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
    Li, Huiping
    Liu, Rongrui
    Shao, Bin
    Ran, Ran
    Song, Guohong
    Wang, Ke
    Shi, Yehui
    Liu, Jihong
    Hu, Wenjing
    Chen, Fu
    Liu, Xiaoran
    Zhang, Gairong
    Zhao, Chuanhua
    Jia, Ru
    Wang, Quanren
    Rugo, Hope S.
    Zhang, Yifan
    Li, Guangze
    Xu, Jianming
    CHINESE JOURNAL OF CANCER RESEARCH, 2020, 32 (03) : 370 - +
  • [36] A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors
    Kyriakopoulos, Christos E.
    Braden, Amy M.
    Kolesar, Jill M.
    Eickhoff, Jens C.
    Bailey, Howard H.
    Heideman, Jennifer
    Liu, Glenn
    Wisinski, Kari B.
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (03) : 290 - 297
  • [37] A phase I study of Triapine® in combination with doxorubicin in patients with advanced solid tumors
    Schelman, William R.
    Morgan-Meadows, Sherry
    Marnocha, Rebecca
    Lee, Fred
    Eickhoff, Jens
    Huang, Wei
    Pomplun, Marcia
    Jiang, Zhisheng
    Alberti, Dona
    Kolesar, Jill M.
    Ivy, Percy
    Wilding, George
    Traynor, Anne M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (06) : 1147 - 1156
  • [38] A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors
    Ruth Plummer
    Ayman Madi
    Melinda Jeffels
    Heike Richly
    Bahar Nokay
    Stephen Rubin
    Howard A. Ball
    Steve Weller
    Jeffrey Botbyl
    Diana M. Gibson
    Max E. Scheulen
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 93 - 101
  • [39] A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors
    Christos E. Kyriakopoulos
    Amy M. Braden
    Jill M. Kolesar
    Jens C. Eickhoff
    Howard H. Bailey
    Jennifer Heideman
    Glenn Liu
    Kari B. Wisinski
    Investigational New Drugs, 2017, 35 : 290 - 297
  • [40] A phase I study of Triapine® in combination with doxorubicin in patients with advanced solid tumors
    William R. Schelman
    Sherry Morgan-Meadows
    Rebecca Marnocha
    Fred Lee
    Jens Eickhoff
    Wei Huang
    Marcia Pomplun
    Zhisheng Jiang
    Dona Alberti
    Jill M. Kolesar
    Percy Ivy
    George Wilding
    Anne M. Traynor
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 1147 - 1156
12345